Head & neck · 2026
Health-Related Quality of Life in Differentiated Thyroid Cancer Survivors: A Cross-Sectional Study From Turkey.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gültekin Aziz, Kahraman Merve Yücel, Şengöz Tarık, Şimşek Fikri Selçuk
Аннотация
BACKGROUND: To evaluate the health-related quality of life (HRQoL) in patients with differentiated thyroid cancer (DTC) and to identify clinical and demographic factors associated with HRQoL outcomes.
METHODS: This cross-sectional study included 202 patients diagnosed with differentiated thyroid cancer who completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) questionnaire. Sociodemographic and clinical data such as age, sex, educational status, employment, tumor size, ATA risk classification, TNM stage, and radioactive iodine (RAI) therapy were recorded. Statistical analyses included descriptive statistics, non-parametric tests, Spearman correlation, and multivariable linear regression to determine predictors of global HRQoL score.
RESULTS: The median global HRQoL was 58.3 (IQR: 50.0-75.0). Functional scores were highest in role, emotional, cognitive, and social domains (median 66.7). Fatigue was the most prominent symptom (median: 44.4), followed by pain, dyspnea, and insomnia (each 33.3). Female sex, lower educational level, and higher RAI dose were associated with lower global HRQoL scores. Emotional functioning was significantly lower in patients aged ≥ 55 years. Multivariable regression analysis identified sex, education level, RAI dose, and TNM stage as significant predictors of HRQoL.
CONCLUSION: Despite generally favorable prognoses in DTC, multiple demographic and treatment-related variables significantly influence patient-reported HRQoL. RAI therapy and disease stage may impact HRQoL less than previously assumed. These findings highlight the importance of individualized supportive care strategies in survivorship plans.
METHODS: This cross-sectional study included 202 patients diagnosed with differentiated thyroid cancer who completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) questionnaire. Sociodemographic and clinical data such as age, sex, educational status, employment, tumor size, ATA risk classification, TNM stage, and radioactive iodine (RAI) therapy were recorded. Statistical analyses included descriptive statistics, non-parametric tests, Spearman correlation, and multivariable linear regression to determine predictors of global HRQoL score.
RESULTS: The median global HRQoL was 58.3 (IQR: 50.0-75.0). Functional scores were highest in role, emotional, cognitive, and social domains (median 66.7). Fatigue was the most prominent symptom (median: 44.4), followed by pain, dyspnea, and insomnia (each 33.3). Female sex, lower educational level, and higher RAI dose were associated with lower global HRQoL scores. Emotional functioning was significantly lower in patients aged ≥ 55 years. Multivariable regression analysis identified sex, education level, RAI dose, and TNM stage as significant predictors of HRQoL.
CONCLUSION: Despite generally favorable prognoses in DTC, multiple demographic and treatment-related variables significantly influence patient-reported HRQoL. RAI therapy and disease stage may impact HRQoL less than previously assumed. These findings highlight the importance of individualized supportive care strategies in survivorship plans.